Roanna Ruiz

Stock Analyst at Leerink Partners

(0)
# 4532
Out of 5,329 analysts
77
Total ratings
30.77%
Success rate
-16.46%
Average return
21 Stocks
Name Action PT Current % Upside Ratings Updated
AKBA Akebia Therapeutics
Initiates Coverage On: Outperform
7
2.4 191.67% 1 Apr 28, 2025
XERS Xeris Biopharma Hold...
Maintains: Outperform
5 6
4.49 33.63% 5 Mar 7, 2025
CRMD Cormedix
Initiates Coverage On: Outperform
18
9.64 86.72% 1 Mar 7, 2025
LXRX Lexicon Pharmaceutic...
Downgrades: Market Perform
1
0.72 38.89% 1 Mar 4, 2025
VIR Vir Biotechnology
Maintains: Outperform
18 20
6.11 227.33% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
26 27
14.2 90.14% 4 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
3.01 331.89% 3 Oct 25, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
14
5.48 155.47% 1 Apr 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
330
293.57 12.41% 1 Feb 5, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
58
43.03 34.79% 1 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
25
71.72 -65.14% 1 Apr 11, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
n/a n/a 4 Apr 4, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Market Perform
49
6.08 705.92% 10 Feb 9, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
12 13
2.54 411.81% 7 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
8 6
2.99 100.67% 6 Jan 27, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
19
19.99 -4.95% 1 Dec 20, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
110 120
106.09 13.11% 3 Nov 15, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
75 50
6.03 729.19% 7 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
23 27
n/a n/a 7 Oct 25, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
60 40
10.99 263.97% 6 Oct 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
720 80
n/a n/a 3 Jul 14, 2022